ArticleMovement disorders : official journal of the Movement Disorder Society2017
Targeting α-Synuclein as a therapy for Parkinson's disease: The battle begins.
Article in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between β2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Tetramethylpyrazine Nitrone Promotes the Clearance of Alpha-Synuclein via Nrf2-Mediated Ubiquitin-Proteasome System Activation.Neuromolecular medicine · 2024Article
- Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression.Frontiers in aging neuroscience · 2023Article
- Cooperative inhibition of SNARE-mediated vesicle fusion by α-synuclein monomers and oligomers.Scientific reports · 2021Article
- β-Adrenoceptor Drugs and Parkinson's Disease: A Nationwide Nested Case-Control Study.CNS drugs · 2020Article
- Using global team science to identify genetic parkinson's disease worldwide.Annals of neurology · 2019Article
- Emerging therapies in Parkinson disease - repurposed drugs and new approaches.Nature reviews. Neurology · 2019Review
- Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.Nature reviews. Drug discovery · 2018Review
- A comprehensive analysis of SNCA-related genetic risk in sporadic parkinson disease.Annals of neurology · 2018Article
- Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease.Journal of neurochemistry · 2018Review
- A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism.Frontiers in neurology · 2018Article
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Movement disorders : official journal of the Movement Disorder Society · 2017Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28218461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.